Flash movie failed to load.

 News Releases

Surgeons Complete Clinical Trial on Novel Two-Part Heart Valve: ValveXchange® paves way for CE mark, commercial sale of first serviceable bioprosthetic valve

ValveXchange, Inc.
6080 Greenwood Plaza Blvd.
Greenwood Village, CO 80111
888-822-8998 (toll free)
888-313-3993 (fax)

Notice: ValveXchange, Inc. products have not been approved by the U.S. FDA or any other Regulatory Agencies. This website contains forward looking statements which represent management's best judgment, but are speculative and may not occur as projected or not at all. Please click here for details of the ValveXchange Website Disclaimers and Notices which apply to all users of this Website.

ValveXchange, Inc. (“ValveXchange®” or “VXi”) is dedicated to improving the lives of patients requiring heart valve replacements. VXi is developing a two-piece bioprosthetic tissue valve system that resolves the long standing compromises between conventional mechanical and tissue-based prosthetic valves. Unlike today’s transcatheter valves, the VXi technology is Without Compromise. The VXi exchangeable valve system is being designed to offer leaflet exchange, as well as the original implant, without open-heart surgery and without the safety and longevity compromises of transcatheter approaches.

The VXi System consists of a two-piece valve and the associated tools for replacing the exchangeable tissue leaflets when they wear out. The permanent support frame for the leaflets is being designed to be implanted surgically and transapically without cardiopulmonary bypass... [read more]

View a video of the ValveXchange technology. [view]

Physicians who would like more information about our progress in developing and testing the VXi Exchangeable Heart Valve System can [read more]